US20090176810A1 - Composition for skin external application containing gallocatechin gallate for moisturizing effect on the skin - Google Patents
Composition for skin external application containing gallocatechin gallate for moisturizing effect on the skin Download PDFInfo
- Publication number
- US20090176810A1 US20090176810A1 US12/064,997 US6499706A US2009176810A1 US 20090176810 A1 US20090176810 A1 US 20090176810A1 US 6499706 A US6499706 A US 6499706A US 2009176810 A1 US2009176810 A1 US 2009176810A1
- Authority
- US
- United States
- Prior art keywords
- skin
- composition
- gallocatechin gallate
- quercetin
- theobromine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- WMBWREPUVVBILR-GHTZIAJQSA-N (+)-gallocatechin gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-GHTZIAJQSA-N 0.000 title claims abstract description 38
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 title claims abstract description 38
- LVJJFMLUMNSUFN-UHFFFAOYSA-N gallocatechin gallate Natural products C1=C(O)C=C2OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C1OC(=O)C1=CC(O)=C(O)C(O)=C1 LVJJFMLUMNSUFN-UHFFFAOYSA-N 0.000 title claims abstract description 32
- 230000003020 moisturizing effect Effects 0.000 title claims description 13
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims abstract description 72
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 claims abstract description 72
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 37
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims abstract description 36
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims abstract description 36
- 235000005875 quercetin Nutrition 0.000 claims abstract description 36
- 229960001285 quercetin Drugs 0.000 claims abstract description 36
- 229960004559 theobromine Drugs 0.000 claims abstract description 36
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims abstract description 19
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- 102100028314 Filaggrin Human genes 0.000 claims abstract description 9
- 101710088660 Filaggrin Proteins 0.000 claims abstract description 9
- 102000007236 involucrin Human genes 0.000 claims abstract description 9
- 108010033564 involucrin Proteins 0.000 claims abstract description 9
- 102000023984 PPAR alpha Human genes 0.000 claims abstract 2
- WMBWREPUVVBILR-NQIIRXRSSA-N (-)-gallocatechin gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-NQIIRXRSSA-N 0.000 claims description 7
- 230000000694 effects Effects 0.000 abstract description 32
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 abstract description 13
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 abstract description 13
- 238000001035 drying Methods 0.000 abstract description 9
- 108010029485 Protein Isoforms Proteins 0.000 abstract description 8
- 102000001708 Protein Isoforms Human genes 0.000 abstract description 8
- 210000003491 skin Anatomy 0.000 description 54
- 238000012360 testing method Methods 0.000 description 25
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 11
- 230000008591 skin barrier function Effects 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 230000036572 transepidermal water loss Effects 0.000 description 9
- 238000013400 design of experiment Methods 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 244000269722 Thea sinensis Species 0.000 description 7
- 235000009569 green tea Nutrition 0.000 description 7
- 238000010993 response surface methodology Methods 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 210000000434 stratum corneum Anatomy 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000004909 Moisturizer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001333 moisturizer Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- 238000003718 Dual-Luciferase Reporter Assay System Methods 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229960000735 docosanol Drugs 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- -1 pack Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000003571 reporter gene assay Methods 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- PGHSKTKIQIBATG-ZAAWVBGYSA-N 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one;hydrate Chemical compound O.O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 PGHSKTKIQIBATG-ZAAWVBGYSA-N 0.000 description 1
- ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical class OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 241000593245 Bionia Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010052090 Renilla Luciferases Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000569510 Spino Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 238000000516 activation analysis Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 238000003052 fractional factorial design Methods 0.000 description 1
- 238000003055 full factorial design Methods 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- DWMMZQMXUWUJME-UHFFFAOYSA-N hexadecyl octanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC DWMMZQMXUWUJME-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000010487 meadowfoam seed oil Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 1
- 235000007743 myricetin Nutrition 0.000 description 1
- 229940116852 myricetin Drugs 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000003614 peroxisome proliferator Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 229940080352 sodium stearoyl lactylate Drugs 0.000 description 1
- ODFAPIRLUPAQCQ-UHFFFAOYSA-M sodium stearoyl lactylate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O ODFAPIRLUPAQCQ-UHFFFAOYSA-M 0.000 description 1
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000438 stratum basale Anatomy 0.000 description 1
- 210000000498 stratum granulosum Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229940026510 theanine Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- the present invention relates to a composition for external skin application having a skin-moisturizing effect, which comprises gallocatechin gallate as an active ingredient.
- the composition for external skin application according to the present invention comprises gallocatechin gallate as an active ingredient to activate peroxisome proliferator activated receptor isoform alpha (PPAR- ⁇ ), to stimulate expression of filaggrin and involucrin that are skin-moisturizing factors, and thus to provide excellent anti-drying and skin-moisturizing effects.
- the composition for external skin application according to the present invention may further comprise theobromine and quercetin in addition to gallocatechin gallate to maximize such effects.
- the skin is divided into the epidermis, the dermis and the subcutaneous tissue when viewed from the exterior, and functions to protect the whole organs in the body from variations in temperature and humidity, ultraviolet rays, and other external physical and chemical environmental irritations.
- the epidermis has an important role in preventing evaporation of moisture in the human body.
- the epidermis is divided into the stratum corneum, the stratum granulosum, the stratum spino and the stratum basale. Additionally, keratinocytes present in the stratum corneum serve as bricks and intercellular lipids present between keratinocytes serve as mortar, thereby forming skin barriers (J. Invest. Dermatol. 80 (Suppl.) 44-49, 1983). Further, a high concentration of natural moisturizing factors (NMF) is present in keratinocytes of healthy humans so that the skin retains moisture. For example, amino acids, which are water soluble materials, are effectively bound to moisture, thereby inhibiting moisture from drying on the skin (J. Invest. Dermatol., 54, 24-31, 1970).
- NMF natural moisturizing factors
- a humectant capable of absorbing moisture or an occlusive moisturizer capable of preventing moisture evaporation have been used as moisturizing agents so as to increase moisture retainment in the stratum corneum.
- humectants include glycerin, propylene glycol, 1.3-butylene glycol, polyethylene glycol, sorbitol, sodium 2-pyrrolidone-5-carboxylate, or the like.
- humectants have a disadvantage in that they have a highly sticky and dense feel when applied on the skin.
- lipids such as the occlusive moisturizers, lipids such as ceramides or essential fatty acids and lipid complexes have been used (J. Invest. Dermatol. (5), 731-740, 1994).
- occlusive moisturizers have difficulty in maintaining stability of an emulsified formulation and are not amenable to production of transparent gel-like cosmetic products.
- peroxisome proliferator activated receptors are known nuclear hormone receptors having the three isoforms of ⁇ , ⁇ / ⁇ and ⁇ distributed over various tissues.
- Peroxisome proliferator activated receptor isoform ⁇ also referred to as ‘PPAR- ⁇ ’
- PPAR- ⁇ peroxisome proliferator activated receptor isoform ⁇
- a peroxisome proliferator factor such as a fibric acid derivative
- Lipid activators of PPAR- ⁇ such as linoleic acid, etc.
- linoleic acid etc.
- a skin cosmetic agent utilizing a mechanism of controlling PPAR activities other than a cosmetic composition (WO01/008653) for preventing and treating skin aging.
- the present invention has been made to solve the above-mentioned problems occurring in the prior art.
- the inventors of the present invention have many studies to search for the components that shows a skin-moisturizing effect by controlling activity of the peroxisome proliferator activated receptor isoform alpha (PPAR- ⁇ ), among various factors affecting the skin in terms of skin moisturization and skin protection.
- PPAR- ⁇ peroxisome proliferator activated receptor isoform alpha
- PPAR- ⁇ peroxisome proliferator activated receptor isoform alpha
- the composition further comprises theobromine and quercetin, besides gallocatechin galate, at an optimized ratio, the above effects can be maximized.
- the present invention is based on these findings.
- composition for external skin application having a skin-moisturizing effect, which comprises gallocatechin gallate as an active ingredient.
- the composition for external skin application having a skin-moisturizing effect comprises gallocatechin gallate as an active ingredient.
- the composition further comprises theobromine and quercetin at an optimized ratio.
- FIG. 1 is a graph illustrating how to select an optimal concentration by a response optimizer
- FIG. 2 is a graph illustration how to select an optimal concentration by using an overlaid contour plot
- FIG. 3 is a view showing expression of filaggrin via RT-PCR analysis.
- FIG. 4 is a photographic view showing the epidermal layers observed by carrying out immunohistochemical staining using involucrin antibodies.
- composition for external skin application having a skin-moisturizing effect comprises gallocatechin gallate as an active ingredient to activate the peroxisome proliferator activated receptor isoform alpha (PPAR- ⁇ ) and to provide excellent skin-moisturizing and anti-drying effects.
- PPAR- ⁇ peroxisome proliferator activated receptor isoform alpha
- composition for external skin application having a skin-moisturizing effect may further comprise theobromine and quercetin contained in green tea leaves as active ingredients, in addition to gallocatechin gallate.
- each active ingredient is present in an amount of 0.001 ⁇ 30 wt % based on the total weight of the composition.
- reporter gene assay One of the known methods for determining PPAR activation by observing PPAR activation/inactivation is reporter gene assay (Kliewer et. al., Nature, 1992, 358: 771-774).
- the reporter gene assay includes cloning a base sequence containing a promoter of interest and reporter genes, and injecting the base sequence into eukaryotic cells to activate transcription and to control the expression of a protein. Herein, protein expression increases as the promoter is activated.
- the reporter gene used for the first time is CAT (chloramphenicol acetyltransferase) gene. Recently, luciferase gene has been used widely. In the present invention, a Dual-Luciferase Reporter Assay System Kit available from Promega Co. was used.
- composition for external skin application having a skin-moisturizing effect further comprises theobromine and quercetin contained in green tea leaves as active ingredients, in addition to gallocatechin gallate, at an optimized ratio, it can provide a higher skin-moisturizing effect by activating the peroxisome proliferator activated receptor isoform alpha (PPAR- ⁇ ).
- PPAR- ⁇ peroxisome proliferator activated receptor isoform alpha
- gallocatechin gallate, theobromine and quercetin are used at an optimized ratio as follows: at least 0.4 moles of theobromine and at least 0.4 moles of quercetin in combination with 0.7 moles or less of gallocatechin gallate (GCG); at least 0.3 moles of theobromine and at least 0.3 moles of quercetin in combination with 0.7 ⁇ 1.4 moles of gallocatechin gallate (GCG); and at least 0.2 moles of theobromine and at least 0.2 moles of quercetin in combination with 1.4 moles or more of gallocatechin gallate (GCG).
- DOE Design of Experiments
- DOE is a methodology for designing, performing and statistically analyzing a science study.
- a series of experimental steps is designed and carried out, wherein levels of a controllable input value are gradually varied in order to determine the cause of variance in an output value of a specific step.
- DOE allows systematic approach to calibration, and definition and evaluation of relationships between an experimental process and the resultant values thereof.
- DOE provides various advisable effects.
- DOE enables understanding of the vital few in variance of a parameter, provides a measurement for the effect of vital few upon response parameters, yields measured values and high-quality data more effectively as compared to One-Factor-At-a-Time calibration, permits measurement of uncertainty, minimizes test trials, and permits control of the nuisance variables.
- Such DOE include fractional factorial designs, full factorial designs, response surface methodology, mixture designs, Taguchi designs, or the like.
- composition for external skin application there is no particular limitation in the formulation of the composition for external skin application according to the present invention.
- the composition according to the present invention may be any skin adhesion type cosmetic formulation, such as lotion, skin toner, nourishing toner, nourishing cream, massage cream, pack, gel, essence, or the like.
- the composition according to the present invention may be provided as a transdermal administration form such as lotion, ointment, gel, cream, a patch or a spraying agent.
- each form of the composition for external skin application may further comprise other additives, as desired, according to the particular form and use of the composition.
- CV-1 cells (ATCC CCL 70), i.e. monkey kidney epithelial cell line, were subcultured in a DMEM medium containing 10% bovine fetal serum treated with charcoal/dextrin. A phenol red-free medium was used to avoid the effect of estrogen upon phenol red.
- plasmids used were plasmids having PPRE (PPARs responsive element) as a promoter, followed by firefly luciferase genes as a reporter, the PPRE being activated by PPAR-(gene-containing PPAR- and ligand-bound PPAR-) bound next to the universal promoter expressed under general culture conditions, and a reference plasmid to which renilla luciferase genes were bound.
- PPRE PPARs responsive element
- CV-1 cells were plated on a 24-well microtiter plate at a concentration of 5 ⁇ 10 4 cells per well and cultured for 24 hours. Then, the above three types of plasmid genes were subjected to transient transfection by using a TransFast Kit available from Promega Co. After the cultured product was washed with PBS (phosphate buffered saline) once, the product was treated with a suitable concentration of sample materials, cultured again for 24 hours, and washed with PBS twice. Next, the cells were lysed with PLB (passive lysis buffer, Promega) once, and determined for luciferase activity by using a Dual-Luciferase Reporter Assay System Kit (Promega) in the samples and the controls.
- PLB phosphate buffered saline
- gallocatechin gallate ( ⁇ )GCG
- theobromine and quercetin show a similar degree effect of activating PPAR- ⁇ .
- RSM response surface methodology
- Thd analysis was done using coded units.
- the cell line used in this example was a human keratinocyte HaCaT cell line distributed from Dr. Fusening in the German Cancer Research Center.
- the cells were pipetted into 60 mm dishes in a number of 1 ⁇ 10 5 cells per dish, cultured for one day, and treated with each test sample, followed by culturing for 24 hours.
- the test samples include a negative control (lanes 1 and 5), a mixture of gallocatechin gallate:theobromine:quercetin (130 ⁇ M:100 ⁇ M:100 ⁇ M) (lanes 2 and 6), and a mixture of gallocatechin gallate:theobromine:quercetin (65 ⁇ M:50 ⁇ M:50 ⁇ M) (lanes 3 and 7).
- the cells were cultured in a DMEM (Dulbeco's modified eagles medium, GibcoBRL, Life Technology) containing 10% fetal bovine serum (FBS) at 37° C. under 5% CO 2 .
- the negative control was the cells cultured in the same medium in the absence of any test sample.
- AMV RNA PCR kit
- a primer for filaggrin (Bionia, Korea) was used as a primer for carrying out RT-PCR
- ⁇ -actin was used as an internal control to compare the expression in test samples with each other. The results are shown in FIG. 3 .
- a mixture containing gallocatechine gallate:theobromine:quercetin in a ratio of 130 ⁇ M:100 ⁇ M:100 ⁇ M (lane 2) and a mixture containing gallocatechine gallate:theobromine:quercetin in a ratio of 65 ⁇ M:50 ⁇ M:50 ⁇ M (lane 3) increase expression of filaggrin as compared to the non-treated group as a negative control (lane 1) by about 1.8-2.0 times (lane 1 ⁇ 3 represents filaggrin expression, lane 5 ⁇ 7 represents ⁇ -actin expression, and lane 4 is a 100 bp ladder as a marker). Therefore, it can be expected that a composition for external skin application comprising such mixtures shows skin-protecting and skin-moisturizing effects. Then, the following Experimental Example 4 was carried out.
- each test panel was allowed to answer questions to perform subjective evaluation for the skin moisturizing effect simultaneously with instrumental evaluation.
- the results are shown in the following Table 6.
- the test groups using the compositions of Examples 1 ⁇ 5 comprising gallocatechin, theobromine and quercetin show a significant increase in skin moisture content in a concentration-dependent manner, when compared to the test group using Comparative Example 1. Additionally, even 6 weeks after the application (2 weeks after the completion of the application), the skin moisture content is similar to the skin moisture content measured 1 ⁇ 2 weeks after the application. Thus, it can be seen that skin moisture content can be maintained to a certain degree without new application of the test material.
- the skin toners comprising the above mixture according to the present invention can improve skin drying conditions.
- TEWL 0 TEWL measured right after skin damage
- TEWL X TEWL measured after a predetermined of time
- Example 7 the test groups treated with gallocatechin gallate (Example 6) or with a mixture of gallocatechin gallate:theobromine:quercetin (Example 7) provide a higher skin barrier recovery ratio into normal skin conditions, when compared to the controls (Comparative Examples 2 and 3). In addition to such excellent recovery of the skin barrier, Examples 6 and 7 show a significant increase in skin moisture content. Thus, it can be seen that the composition according to the present invention provides an excellent skin moisturizing effect.
- a piece of skin tissue was cut from the test animals, fixed with paraffin, and was subjected to immunohistochemical staining by using involucrin (INV) antibodies, while observing variations in the epidermal layers. The results are shown in FIG. 4 . Involucrin was observed as the part stained with a brown color.
- Example 6 the test groups to which gallocatechin gallate (Example 6) or a mixture of gallocatechin:theobromine:quercetin (Example 7) was applied show an increase in involucrin expression as compared to the control (Comparative Example 2). This indicates that the composition according to the present invention can provide an excellent effect of improving damaged skin barriers.
- composition for external skin application having a skin moisturizing effect comprises gallocatechin gallate contained in green tea leaves to control the activity of PPAR- ⁇ .
- the composition according to the present invention may further comprise theobromine and quercetin at an optimized ratio to provide an enhanced skin moisturizing effect and anti-drying effect.
Abstract
The present invention relates to a composition for external skin application having a skin-moisturizing effect, which comprises gallocatechin gallate as an active ingredient. More particularly, the composition for external skin application comprises gallocatechin gallate as an active ingredient to activate peroxisome proliferator activated receptor isoform alpha (PPAR-α), to stimulate expression of filaggrin and involucrin that are skin-moisturizing factors, and thus to provide excellent anti-drying and skin-moisturizing effects. More particularly, the composition for external skin application may further comprise theobromine and quercetin in addition to gallocatechin gallate to maximize such effects.
Description
- The present invention relates to a composition for external skin application having a skin-moisturizing effect, which comprises gallocatechin gallate as an active ingredient. More particularly, the composition for external skin application according to the present invention comprises gallocatechin gallate as an active ingredient to activate peroxisome proliferator activated receptor isoform alpha (PPAR-α), to stimulate expression of filaggrin and involucrin that are skin-moisturizing factors, and thus to provide excellent anti-drying and skin-moisturizing effects. More particularly, the composition for external skin application according to the present invention may further comprise theobromine and quercetin in addition to gallocatechin gallate to maximize such effects.
- In general, the skin is divided into the epidermis, the dermis and the subcutaneous tissue when viewed from the exterior, and functions to protect the whole organs in the body from variations in temperature and humidity, ultraviolet rays, and other external physical and chemical environmental irritations. Particularly, the epidermis has an important role in preventing evaporation of moisture in the human body.
- The epidermis is divided into the stratum corneum, the stratum granulosum, the stratum spino and the stratum basale. Additionally, keratinocytes present in the stratum corneum serve as bricks and intercellular lipids present between keratinocytes serve as mortar, thereby forming skin barriers (J. Invest. Dermatol. 80 (Suppl.) 44-49, 1983). Further, a high concentration of natural moisturizing factors (NMF) is present in keratinocytes of healthy humans so that the skin retains moisture. For example, amino acids, which are water soluble materials, are effectively bound to moisture, thereby inhibiting moisture from drying on the skin (J. Invest. Dermatol., 54, 24-31, 1970).
- However, skin drying and roughening phenomena, caused by a drop in moisture content of the stratum corneum and including loose, dry and inanimate skin conditions, occur due to various causes. Such causes include artificial temperature control for cooling/warming an indoor space depending on variations in the living environment and pattern, diverse stresses generated from social activities and skin stresses caused by environmental pollution, frequent face-washing depending on makeup habits, and natural skin aging. Therefore, there has been an increasing need for a skin moisturizing agent.
- According to the prior art, a humectant capable of absorbing moisture or an occlusive moisturizer capable of preventing moisture evaporation have been used as moisturizing agents so as to increase moisture retainment in the stratum corneum. Such humectants include glycerin, propylene glycol, 1.3-butylene glycol, polyethylene glycol, sorbitol, sodium 2-pyrrolidone-5-carboxylate, or the like. However, such humectants have a disadvantage in that they have a highly sticky and dense feel when applied on the skin. Additionally, as the occlusive moisturizers, lipids such as ceramides or essential fatty acids and lipid complexes have been used (J. Invest. Dermatol. (5), 731-740, 1994). However, such occlusive moisturizers have difficulty in maintaining stability of an emulsified formulation and are not amenable to production of transparent gel-like cosmetic products.
- Meanwhile, peroxisome proliferator activated receptors (PPAR) are known nuclear hormone receptors having the three isoforms of α, β/δ and γ distributed over various tissues. Peroxisome proliferator activated receptor isoform α (also referred to as ‘PPAR-α’) has been identified first based on the mechanism of controlling genes encoding fatty acid oxidase by the reaction with a peroxisome proliferator factor such as a fibric acid derivative (Issemann and Green, Nature, 1990, 347: 645-650). Additionally, it is disclosed that fatty acids play an important role in tissues expressed by PPAR-α (Leone et al., Proc. Natl. Acad. Sci. USA, 1999, 96: 7473-7478). Lipid activators of PPAR-α, such as linoleic acid, etc., are known to those skilled in the art. It is demonstrated that such activators enhance formation of an epithelial barrier in vitro (Hanley et. al., J. Clin. Inv., 1977, 100: 705-712). However, in the relevant art, there is no disclosure of a skin cosmetic agent utilizing a mechanism of controlling PPAR activities other than a cosmetic composition (WO01/008653) for preventing and treating skin aging.
- Accordingly, the present invention has been made to solve the above-mentioned problems occurring in the prior art. The inventors of the present invention have many studies to search for the components that shows a skin-moisturizing effect by controlling activity of the peroxisome proliferator activated receptor isoform alpha (PPAR-α), among various factors affecting the skin in terms of skin moisturization and skin protection. Then, we have found that when a composition for external skin application comprises gallocatechin gallate contained in green tea leaves, it activates the peroxisome proliferator activated receptor isoform alpha (PPAR-α) and stimulates expression of skin moisturizing factors such as filaggrin and involucrin, and thus provides excellent skin moisturizing and anti-drying effects. Particularly, we have also found that when the composition further comprises theobromine and quercetin, besides gallocatechin galate, at an optimized ratio, the above effects can be maximized. The present invention is based on these findings.
- Therefore, it is an object of the present invention to provide a composition for external skin application having a skin-moisturizing effect, which comprises gallocatechin gallate as an active ingredient.
- It is another object of the present invention to provide a composition for external skin application having a skin-moisturizing effect, which further comprises theobromine and quercetin at an optimized ratio in addition to the above composition comprising gallocatechin gallate.
- According to an aspect of the present invention, the composition for external skin application having a skin-moisturizing effect comprises gallocatechin gallate as an active ingredient. According to another aspect of the present invention, the composition further comprises theobromine and quercetin at an optimized ratio.
- Further objects and advantages of the invention can be more fully understood from the following detailed description taken in conjunction with the accompanying drawings, in which:
-
FIG. 1 is a graph illustrating how to select an optimal concentration by a response optimizer; -
FIG. 2 is a graph illustration how to select an optimal concentration by using an overlaid contour plot; -
FIG. 3 is a view showing expression of filaggrin via RT-PCR analysis; and -
FIG. 4 is a photographic view showing the epidermal layers observed by carrying out immunohistochemical staining using involucrin antibodies. - Hereinafter, the present invention will be explained in more detail.
- The composition for external skin application having a skin-moisturizing effect according to the present invention comprises gallocatechin gallate as an active ingredient to activate the peroxisome proliferator activated receptor isoform alpha (PPAR-α) and to provide excellent skin-moisturizing and anti-drying effects.
- Additionally, the composition for external skin application having a skin-moisturizing effect may further comprise theobromine and quercetin contained in green tea leaves as active ingredients, in addition to gallocatechin gallate.
- In the composition for external skin application having a skin-moisturizing effect according to the present invention, each active ingredient is present in an amount of 0.001˜30 wt % based on the total weight of the composition.
- One of the known methods for determining PPAR activation by observing PPAR activation/inactivation is reporter gene assay (Kliewer et. al., Nature, 1992, 358: 771-774). The reporter gene assay includes cloning a base sequence containing a promoter of interest and reporter genes, and injecting the base sequence into eukaryotic cells to activate transcription and to control the expression of a protein. Herein, protein expression increases as the promoter is activated. The reporter gene used for the first time is CAT (chloramphenicol acetyltransferase) gene. Recently, luciferase gene has been used widely. In the present invention, a Dual-Luciferase Reporter Assay System Kit available from Promega Co. was used.
- Meanwhile, when the composition for external skin application having a skin-moisturizing effect according to the present invention further comprises theobromine and quercetin contained in green tea leaves as active ingredients, in addition to gallocatechin gallate, at an optimized ratio, it can provide a higher skin-moisturizing effect by activating the peroxisome proliferator activated receptor isoform alpha (PPAR-α).
- In the composition for external skin application according to the present invention, gallocatechin gallate, theobromine and quercetin are used at an optimized ratio as follows: at least 0.4 moles of theobromine and at least 0.4 moles of quercetin in combination with 0.7 moles or less of gallocatechin gallate (GCG); at least 0.3 moles of theobromine and at least 0.3 moles of quercetin in combination with 0.7˜1.4 moles of gallocatechin gallate (GCG); and at least 0.2 moles of theobromine and at least 0.2 moles of quercetin in combination with 1.4 moles or more of gallocatechin gallate (GCG).
- When analyzing functions of various components contained in green tea leaves, an integrated experimental and analytical process is required to obtain the greatest information under a given estimated cost in a predetermined time. For this purpose, DOE (Design of Experiments) has been used. DOE is a methodology for designing, performing and statistically analyzing a science study. Particularly, according to DOE, a series of experimental steps is designed and carried out, wherein levels of a controllable input value are gradually varied in order to determine the cause of variance in an output value of a specific step. By doing so, it is possible to construct an experimental strategy for determining experimental conditions under which the greatest information can be obtained efficiently so as to satisfy objects of the experiment and to obtain adequate results. DOE allows systematic approach to calibration, and definition and evaluation of relationships between an experimental process and the resultant values thereof. Additionally, DOE provides various advisable effects. For example, DOE enables understanding of the vital few in variance of a parameter, provides a measurement for the effect of vital few upon response parameters, yields measured values and high-quality data more effectively as compared to One-Factor-At-a-Time calibration, permits measurement of uncertainty, minimizes test trials, and permits control of the nuisance variables. Such DOE include fractional factorial designs, full factorial designs, response surface methodology, mixture designs, Taguchi designs, or the like.
- There is no particular limitation in the formulation of the composition for external skin application according to the present invention. The composition according to the present invention may be any skin adhesion type cosmetic formulation, such as lotion, skin toner, nourishing toner, nourishing cream, massage cream, pack, gel, essence, or the like. Also, the composition according to the present invention may be provided as a transdermal administration form such as lotion, ointment, gel, cream, a patch or a spraying agent. Additionally, each form of the composition for external skin application may further comprise other additives, as desired, according to the particular form and use of the composition.
- Hereinafter, the present invention will be explained in more detail with reference to examples and experimental examples. However, the following examples are illustrative only, and the scope of the present invention is not limited thereto.
- The following test was carried out to determine PPAR-A activation capability.
- CV-1 cells (ATCC CCL 70), i.e. monkey kidney epithelial cell line, were subcultured in a DMEM medium containing 10% bovine fetal serum treated with charcoal/dextrin. A phenol red-free medium was used to avoid the effect of estrogen upon phenol red. As plasmids, used were plasmids having PPRE (PPARs responsive element) as a promoter, followed by firefly luciferase genes as a reporter, the PPRE being activated by PPAR-(gene-containing PPAR- and ligand-bound PPAR-) bound next to the universal promoter expressed under general culture conditions, and a reference plasmid to which renilla luciferase genes were bound.
- CV-1 cells were plated on a 24-well microtiter plate at a concentration of 5×104 cells per well and cultured for 24 hours. Then, the above three types of plasmid genes were subjected to transient transfection by using a TransFast Kit available from Promega Co. After the cultured product was washed with PBS (phosphate buffered saline) once, the product was treated with a suitable concentration of sample materials, cultured again for 24 hours, and washed with PBS twice. Next, the cells were lysed with PLB (passive lysis buffer, Promega) once, and determined for luciferase activity by using a Dual-Luciferase Reporter Assay System Kit (Promega) in the samples and the controls. In this test, as a positive control, Wy14643 known as the strongest PPAR-α ligand was used. As negative controls, DMSO used to dissolve the samples and non-treated group were used. Each reported value was calculated as a ratio based on the negative control. The results are shown in the following Table 1, wherein each value is the mean value obtained after carrying out the test three times.
-
TABLE 1 Results for PPAR-γ activation analysis PPAR-α Activation 10 uM 100 uM (−) EGCG 1.0 1.5 (−) GCG 1.1 2.3 (−) ECG 1.1 1.6 (−) CG 1.2 1.6 (−) EGC 1.3 1.0 (−) GC 1.1 1.0 (−) EC 1.2 1.2 (+) EC 1.3 1.2 (−) CA 1.4 1.2 (+) CA 1.5 1.4 Gallic acid 1.3 1.7 Caffeine 1.3 1.6 Quercetin 1.7 2.3 Kaempferol 1.7 1.4 Theobromine 2.2 4.5 Theophylline 1.4 1.7 Theanine 1.8 1.9 Rutin hydrate 1.6 1.3 Quinic acid 1.3 1.7 Myricetin 1.7 1.6 Negative control 1.0 1.0 0.1 uM 1 uM 10 uM Positive Control 1.5 2.6 3.8 - As can be seen from Table 1, among various components contained in green tea leave, gallocatechin gallate ((−)GCG), theobromine and quercetin show a similar degree effect of activating PPAR-α.
- To optimize the PPAR-α activation capability of the components contained in green tea leaves, i.e. gallocatechin gallate, theobromine and quercetin, PPAR-α activation capability of which was determined in Experimental Example 1, response surface methodology (RSM) was used. When using RSM, it is possible to understand the level of an independent parameter where a response value is optimized, to estimate the effect of an independent parameter upon response parameters via estimation of a functional relationship between each independent parameter and dependent parameter, and to determine optimized experimental conditions. According to the present invention, central composite designs of RSM were carried out by using MiniTab 14. The results are shown in the following Table 2.
-
TABLE 2 Central Composite Designs and Measurements Thereof C5 C6 C7 C8 C9 C10 C11 C12 ↓ GCG theobromine quercetin StdOrder_1 RunOrder_1 Blocks_1 PtType_1 fold 1 0 0 0 1 1 1 1 1.68624 2 100 0 0 2 2 1 1 1.19051 3 0 100 0 3 3 1 1 1.90453 4 100 100 0 4 4 1 1 2.65788 5 0 0 100 5 5 1 1 1.29988 6 100 0 100 6 6 1 1 2.02023 7 0 100 100 7 7 1 1 3.86848 8 100 100 100 8 8 1 1 4.05643 9 0 50 50 9 9 1 1 3.49402 10 135 50 50 10 10 1 1 4.65930 11 50 0 50 11 11 1 1 2.25292 12 50 135 50 12 12 1 1 4.05384 13 50 50 0 13 13 1 1 1.99345 14 50 50 135 14 14 1 1 4.16529 15 50 50 50 15 15 1 1 4.66230 16 50 50 50 16 16 1 1 3.53491 17 50 50 50 17 17 1 1 3.66928 18 50 50 50 18 18 1 1 3.56013 19 50 50 50 19 19 1 1 3.91237 20 50 50 50 20 20 1 1 2.99202 - Then, an experiment was performed according to the above designs as shown in Table 2, and software analysis was carried out by using the values measured from the experiment.
- Response Surface Regression: fold versus GCG, theobromine, quercetin
- Thd analysis was done using coded units.
-
Estimated Regression Coefficients for fold Term Coef SE Coef T P Constant 4.2440 0.2165 19.600 0.000 GCG 0.3420 0.2323 1.472 0.165 theobromine 0.8182 0.2738 2.988 0.010 quercetin 0.6292 0.2738 2.298 0.039 theobromine*theobromine −1.1066 0.3580 −3.091 0.009 quercetin*quercetin −0.9463 0.3580 −2.643 0.020 theobromine*quercetin 0.6651 0.3814 1.744 0.105% S = 0.5918 R-Sq = 80.7% R-Sq(adj) = 71.8 Analysis of Variance for fold Source DF Seq SS Adj SS Adj HS F P Regression 6 19.052 19.052 3.1753 9.07 0.001 Linear 3 11.367 5.078 1.6928 4.83 0.018 Square 2 6.619 6.619 3.3096 9.45 0.003 Interaction 1 1.065 1.065 1.0653 3.04 0.105 Residual Error 13 4.554 4.554 0.3503 Lack-of-Fit 8 3.036 3.036 0.3795 1.25 0.420 Pure Error 5 1.517 1.517 0.3035 Total 19 23.605 Unusual Observations for fold Obs StdOrder fold Fit Se Fit Residual St Resid I 14 14 4.165 3.379 0.495 0.786 2.42 R R denotes an observation with a large standardized residual. - The results are shown in
FIGS. 1 and 2 and the following Table 3. -
TABLE 3 Optimized Concentration Ratio for PPAR-α Activation Component Concentration Ratio Gallocatechin gallate (GCG) 0.7 or less 0.7~1.4 1.4 or more Theobromine At least 0.4 At least 0.3 At least 0.2 Quercetin At least 0.4 At least 0.3 At least 0.2 - As can be seen from the results of the software analysis, R2=80.7% and R2 (adj)=71.8%, which indicate a relatively high interrelation. Also, regression simulation shows similar results. Additionally, it is possible to recognize from the response optimizer as shown in
FIG. 1 that the optimized concentration conditions showing the highest value according to the larger-the-better characteristics are accomplished at 135 μM of gallocatechin gallate, 100 μM of theobromine and 100 μM of quercetin. Further, it is possible to estimate optimal concentration ranges by using the overlaid contour plot as shown inFIG. 2 . The results are shown in the above Table 3. - The cell line used in this example was a human keratinocyte HaCaT cell line distributed from Dr. Fusening in the German Cancer Research Center. The cells were pipetted into 60 mm dishes in a number of 1×105 cells per dish, cultured for one day, and treated with each test sample, followed by culturing for 24 hours. The test samples include a negative control (lanes 1 and 5), a mixture of gallocatechin gallate:theobromine:quercetin (130 μM:100 μM:100 μM) (
lanes 2 and 6), and a mixture of gallocatechin gallate:theobromine:quercetin (65 μM:50 μM:50 μM) (lanes 3 and 7). The cells were cultured in a DMEM (Dulbeco's modified eagles medium, GibcoBRL, Life Technology) containing 10% fetal bovine serum (FBS) at 37° C. under 5% CO2. The negative control was the cells cultured in the same medium in the absence of any test sample. - From the cells cultured and tested in the manner as described above, the total RNA was extracted by using trizol (Gibco Laboratories, USA), and RT-PCR (reverse transcriptional polymerase chain reaction) analysis was carried out according to the method provided by a one-step RNA PCR kit (AMV) (Takara Bio Inc., Japan). Herein, a primer for filaggrin (Bionia, Korea) was used as a primer for carrying out RT-PCR, and β-actin was used as an internal control to compare the expression in test samples with each other. The results are shown in
FIG. 3 . - As can be seen from
FIG. 3 , a mixture containing gallocatechine gallate:theobromine:quercetin in a ratio of 130 μM:100 μM:100 μM (lane 2) and a mixture containing gallocatechine gallate:theobromine:quercetin in a ratio of 65 μM:50 μM:50 μM (lane 3) increase expression of filaggrin as compared to the non-treated group as a negative control (lane 1) by about 1.8-2.0 times (lane 1˜3 represents filaggrin expression, lane 5˜7 represents β-actin expression, and lane 4 is a 100 bp ladder as a marker). Therefore, it can be expected that a composition for external skin application comprising such mixtures shows skin-protecting and skin-moisturizing effects. Then, the following Experimental Example 4 was carried out. - The skin toners of Examples 1˜5 and Comparative Example 1 prepared according to the following Table 4 were determined for skin moisturizing effects.
- Fifty men and women at their fifties to eighties showing a skin drying phenomenon were divided into five groups. Each group was allowed to use the skin toners of Examples 1˜5 and Comparative Example 1 on their faces. Skin moisture content was measured before the application, 1 week, 2 weeks and 4 weeks after the application, and 2 weeks after the completion of the application (i.e. 6 weeks after the application) under constant temperature/constant humidity (24° C.,
relative humidity 40%) conditions by using a koniometer. The results are shown in the following Table 5. Each value listed in Table 5 is expressed as a percent ratio of an increase in the corresponding value measured after a predetermined period of time based on the value measured by the koniometer right before starting the test. The koniometer is a device for measuring skin moisture content by measuring electric conductivity on the epidermis. - Separately from the above test, each test panel was allowed to answer questions to perform subjective evaluation for the skin moisturizing effect simultaneously with instrumental evaluation. The results are shown in the following Table 6.
-
TABLE 4 Component (amount, wt %) Ex. 1 Ex. 2 Ex. 3 Ex. 4 Ex. 5 Comp. Ex. 1 1 Purified water 65.82 65.82 64.82 61.82 56.82 66.82 2 Gallocatechin gallate 1 — — — — — 3 Mixture of gallocatechin — 1 2 5 10 — gallate:theobromine:quercetin (1.3:1:1) 4 Vegetable cured oil 1.50 1.50 1.50 1.50 1.50 1.50 5 Stearic acid 0.60 0.60 0.60 0.60 0.60 0.60 6 Polygrlycerol-10 pentastearate 1.00 1.00 1.00 1.00 1.00 1.00 & behenyl alcohol & sodium stearoyl lactylate 7 Arachidyl behenyl alcohol & 1.00 1.00 1.00 1.00 1.00 1.00 arachydyl glucoside 8 Ceteraryl alcohol & cetearyl 2.00 2.00 2.00 2.00 2.00 2.00 glucoside 9 PEG-100 stearate & glycerol 1.50 1.50 1.50 1.50 1.50 1.50 oleate & propylene glycol 10 Caprylic/Capric triglyceride 4.00 4.00 4.00 4.00 4.00 4.00 11 Meadowfoam seed oil 3.00 3.00 3.00 3.00 3.00 3.00 12 Cetyl octanoate 4.00 4.00 4.00 4.00 4.00 4.00 13 Cyclomethicone 6.00 6.00 6.00 6.00 6.00 6.00 14 Methyl paraben 0.20 0.20 0.20 0.20 0.20 0.20 15 Propyl paraben 0.10 0.10 0.10 0.10 0.10 0.10 16 Disodium EDTA 0.02 0.02 0.02 0.02 0.02 0.02 17 Triethanol amine 0.13 0.13 0.13 0.13 0.13 0.13 18 Glycerin 8.00 8.00 8.00 8.00 8.00 8.00 19 Carbomer 0.13 0.13 0.13 0.13 0.13 0.13 -
TABLE 5 Measurement of Moisture Content Moisture content increase (%) After 1 After 2 After 4 After 6 Test group week weeks weeks weeks Ex. 1 32 38 40 34 Ex. 2 38 41 42 36 Ex. 3 40 42 44 36 Ex. 4 41 46 50 41 Ex. 5 44 42 53 43 Comp. Ex. 1 22 24 24 15 -
TABLE 6 Evaluation via Answer to Questions Excellent Good Moderate Poor Ex. 1 1 5 3 1 Ex. 2 2 4 3 1 Ex. 3 2 6 2 0 Ex. 4 3 6 1 0 Ex. 5 4 4 2 0 Comp. Ex. 1 1 1 5 3 - As shown in Table 5, the test groups using the compositions of Examples 1˜5 comprising gallocatechin, theobromine and quercetin show a significant increase in skin moisture content in a concentration-dependent manner, when compared to the test group using Comparative Example 1. Additionally, even 6 weeks after the application (2 weeks after the completion of the application), the skin moisture content is similar to the skin moisture content measured 1˜2 weeks after the application. Thus, it can be seen that skin moisture content can be maintained to a certain degree without new application of the test material.
- Also, as can be seen from the results of the examination listed in Table 6, the skin toners comprising the above mixture according to the present invention can improve skin drying conditions.
- The following test was carried out to determine the effect of the composition according to the present invention upon recovery of skin barriers on the skin damaged for a long period of time. Acetone was applied onto the backs of 8˜10 week-aged young hairless rats in a periodic manner twice per day for 5 days, so that the back skin of the test animals was damaged in terms of skin barrier functions. Then, TEWL (transepidermal water loss) was measured by using an evaporimeter to select test animals showing a TEWL of 40 g/m2/hr or more. To the selected test animals, vehicle (propylene glycol:ethanol=7:3) and the test materials comprising the compositions of Examples 6 and 7 and Comparative Examples 2 and 3 as shown in the following Table 7 were applied continuously in a dose of 200 d per 5 cm2 of skin area twice per day for 3 days. During the application, TEWL was measured at predetermined intervals, and a skin barrier recovery ratio was calculated according to the following Mathematical Formula 1. The results are shown in the following Table 7.
-
Skin barrier recovery ratio(%)=(TEWL 0 −TEWL X)/(TEWL 0 −TEWL basal)×100 [Mathematical Formula 1] - TEWL0: TEWL measured right after skin damage
- TEWLX: TEWL measured after a predetermined of time
- TEWLbasal: initial TEWL value
-
TABLE 7 Skin Barrier Recovery Ratio (%) Item Test Sample 0 hr 3 hr 6 hr 30 hr Comp. Ex. 2 Control (PG:EtOH = 7:3) 0 25 34 74 Comp. Ex. 3 Epigallocatechin gallate 0 42 50 79 (EGCG) 1% Ex. 6 Gallocatechin gallate 0 46 53 84 (GCG) 1% Ex. 7 Gallocatechin gallate: 0 33 55 96 theobromine:quercetin (1.3:1:1) mixture 1% - As shown in Table 7, the test groups treated with gallocatechin gallate (Example 6) or with a mixture of gallocatechin gallate:theobromine:quercetin (Example 7) provide a higher skin barrier recovery ratio into normal skin conditions, when compared to the controls (Comparative Examples 2 and 3). In addition to such excellent recovery of the skin barrier, Examples 6 and 7 show a significant increase in skin moisture content. Thus, it can be seen that the composition according to the present invention provides an excellent skin moisturizing effect.
- Additionally, a piece of skin tissue was cut from the test animals, fixed with paraffin, and was subjected to immunohistochemical staining by using involucrin (INV) antibodies, while observing variations in the epidermal layers. The results are shown in
FIG. 4 . Involucrin was observed as the part stained with a brown color. - As can be seen from
FIG. 4 , the test groups to which gallocatechin gallate (Example 6) or a mixture of gallocatechin:theobromine:quercetin (Example 7) was applied show an increase in involucrin expression as compared to the control (Comparative Example 2). This indicates that the composition according to the present invention can provide an excellent effect of improving damaged skin barriers. - The composition for external skin application having a skin moisturizing effect according to the present invention comprises gallocatechin gallate contained in green tea leaves to control the activity of PPAR-α. The composition according to the present invention may further comprise theobromine and quercetin at an optimized ratio to provide an enhanced skin moisturizing effect and anti-drying effect.
Claims (10)
1-9. (canceled)
10. A composition for external skin application having a skin moisturizing effect, which comprises gallocatechin gallate as an active ingredient.
11. The composition for external skin application according to claim 10 , which further comprises theobromine and quercetin as active ingredients.
12. The composition for external skin application according to claim 11 , wherein each active ingredient is used in the following molar concentration: at least 0.4 moles of theobromine and at least 0.4 moles of quercetin in combination with 0.7 moles or less of gallocatechin gallate (GCG).
13. The composition for external skin application according to claim 11 , wherein each active ingredient is used in the following molar concentration: at least 0.3 moles of theobromine and at least 0.3 moles of quercetin in combination with 0.7˜1.4 moles or less of gallocatechin gallate (GCG).
14. The composition for external skin application according to claim 11 , wherein each active ingredient is used in the following molar concentration: at least 0.2 moles of theobromine and at least 0.2 moles of quercetin in combination with 1.4 moles or more of gallocatechin gallate (GCG).
15. The composition for external skin application according to claim 10 , wherein each active ingredient is used in an amount of 0.00130.0 wt % based on the total weight of the composition.
16. The composition for external skin application according to claim 10 , which activates PPAR-α.
17. The composition for external skin application according to claim 10 , which stimulates expression of filaggrin on the skin.
18. The composition for external skin application according to claim 10 , which stimulates expression of involucrin on the skin.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2005-0086821 | 2005-09-16 | ||
KR1020050086821A KR100659138B1 (en) | 2005-09-16 | 2005-09-16 | Composition for skin external application containing gallocatechin gallate for moisturizing effect |
PCT/KR2006/003579 WO2007032624A1 (en) | 2005-09-16 | 2006-09-08 | Composition for skin external application containing gallocatechin gallate for moisturizing effect on the skin |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2006/003579 A-371-Of-International WO2007032624A1 (en) | 2005-09-16 | 2006-09-08 | Composition for skin external application containing gallocatechin gallate for moisturizing effect on the skin |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/067,719 Division US8563564B2 (en) | 2005-09-16 | 2011-06-22 | Composition for skin external application containing gallocatechin gallate for moisturizing effect on the skin |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090176810A1 true US20090176810A1 (en) | 2009-07-09 |
Family
ID=37814815
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/064,997 Abandoned US20090176810A1 (en) | 2005-09-16 | 2006-09-08 | Composition for skin external application containing gallocatechin gallate for moisturizing effect on the skin |
US13/067,719 Active US8563564B2 (en) | 2005-09-16 | 2011-06-22 | Composition for skin external application containing gallocatechin gallate for moisturizing effect on the skin |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/067,719 Active US8563564B2 (en) | 2005-09-16 | 2011-06-22 | Composition for skin external application containing gallocatechin gallate for moisturizing effect on the skin |
Country Status (4)
Country | Link |
---|---|
US (2) | US20090176810A1 (en) |
JP (1) | JP5524483B2 (en) |
KR (1) | KR100659138B1 (en) |
WO (1) | WO2007032624A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011038210A3 (en) * | 2009-09-25 | 2011-10-20 | Opkocurna, Inc. | Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity |
US9132294B2 (en) | 2010-06-30 | 2015-09-15 | Avon Products, Inc. | Compositions and methods for stimulation MAGP-1 to improve the appearance of skin |
US9409860B2 (en) | 2010-06-30 | 2016-08-09 | Avon Products Inc. | Cosmetic use of N-substituted sulfonyloxybenzylamines and related compounds |
US10336797B2 (en) | 2009-11-23 | 2019-07-02 | Research Development Foundation | Recombinant filaggrin polypeptides for cell importation |
WO2022122167A1 (en) | 2020-12-11 | 2022-06-16 | Symrise Ag | Medicament for preventing or treating pathologic conditions of human skin (i) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5761888B2 (en) * | 2008-09-30 | 2015-08-12 | 丸善製薬株式会社 | Anti-aging agent and skin cosmetics |
KR101326932B1 (en) * | 2009-11-26 | 2013-11-11 | (주)아모레퍼시픽 | Composition for Promotion of Peroxisome proliferator activated receptor delta |
FR2973704B1 (en) | 2011-04-11 | 2014-09-05 | Fabre Pierre Dermo Cosmetique | PEPTIDYL-ARGININE 1 AND / OR 3 EPIDERM ACTIVATOR COMPOUNDS IN EPIDERM AND USES THEREOF |
KR101914157B1 (en) * | 2011-08-24 | 2018-12-31 | (주)아모레퍼시픽 | Cosmetic composition comprising camellia sinensis constituents |
US20140343034A1 (en) * | 2013-04-25 | 2014-11-20 | Japan Tobacco Inc. | Skin barrier function improving agent |
CN103585040B (en) * | 2013-10-31 | 2015-07-22 | 天津郁美净集团有限公司 | Emulsion composition used for water resistant liquid crystal cosmetics and application thereof |
JP6393524B2 (en) * | 2014-06-05 | 2018-09-19 | ロート製薬株式会社 | Moisturizer |
KR20160096839A (en) | 2015-02-06 | 2016-08-17 | 담양군 | Nourising cream containing blueberry extract collected in hydrogel |
US10417127B2 (en) * | 2017-07-13 | 2019-09-17 | International Business Machines Corporation | Selective downstream cache processing for data access |
KR20200061367A (en) * | 2017-09-29 | 2020-06-02 | 산토리 홀딩스 가부시키가이샤 | Composition for promoting aquaporin 3 expression and use thereof |
KR102611023B1 (en) * | 2018-11-21 | 2023-12-08 | (주)아모레퍼시픽 | Composition for skin barrier strengthening or moisturizing external skin application containing dehydrogenated abietic acid |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5665367A (en) * | 1996-09-27 | 1997-09-09 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Skin care compositions containing naringenin and/or quercetin and a retinoid |
US20020106388A1 (en) * | 2000-11-24 | 2002-08-08 | Pugliese Peter T. | Formulation of flavones and isoflavones for treatment of cellulite |
US20030211184A1 (en) * | 1999-02-02 | 2003-11-13 | Archer-Daniels-Midland Company | Process for extracting polyphenolic antioxidants from purine-containing plants |
US20040161435A1 (en) * | 2003-02-14 | 2004-08-19 | Gupta Shyam K. | Skin Firming Anti-Aging Cosmetic Mask Compositions |
US20050003024A1 (en) * | 2003-03-04 | 2005-01-06 | The Procter & Gamble Company | Regulation of mammalian hair growth |
US20050031737A1 (en) * | 2002-11-22 | 2005-02-10 | Lines Thomas Christian | Antioxidative compositions |
US6861062B2 (en) * | 2000-03-01 | 2005-03-01 | Victor Silva | Skin cream |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9404303D0 (en) * | 1994-03-04 | 1994-04-20 | Royal Free Hosp School Med | Antibacterial agent |
JP3492754B2 (en) * | 1994-03-17 | 2004-02-03 | 花王株式会社 | Bath composition |
FR2754713B1 (en) * | 1996-10-22 | 1999-01-08 | Roc Sa | USE OF COMPLEXES FOR THE PREPARATION OF COMPOSITIONS FOR THE TREATMENT OF SENSITIVE SKIN, PREPARATION METHOD AND HYPOALLERGENIC COMPOSITIONS |
KR100306847B1 (en) * | 1996-12-26 | 2001-12-28 | 성재갑 | Cosmetic composition for whole body |
JP2001509165A (en) * | 1997-01-24 | 2001-07-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Use of FXR, PPARα and LXRα activators for restoring barrier function, promoting epidermal differentiation and inhibiting proliferation |
JP4082823B2 (en) | 1999-05-06 | 2008-04-30 | 日本メナード化粧品株式会社 | Phototoxicity inhibitor |
EP1077211B1 (en) * | 1999-08-16 | 2006-11-22 | DSM IP Assets B.V. | Process for the production of epigallocatechin gallate |
FI20000004A0 (en) * | 2000-01-03 | 2000-01-03 | Slk Foundation | Flavonoidilääke ... |
JP4719372B2 (en) * | 2000-06-21 | 2011-07-06 | 花王株式会社 | PPAR-dependent gene transcription activator |
JP2002069496A (en) * | 2000-08-28 | 2002-03-08 | Yushi Seihin Kk | Dark brown solid toilet soap |
US6596313B2 (en) * | 2001-08-06 | 2003-07-22 | The Quigley Corporation | Nutritional supplement and methods of using it |
EP1545579A1 (en) * | 2002-07-31 | 2005-06-29 | Procyte Corporation | Compositions containing peptide copper complexes and phytochemical compounds, and methods related thereto |
-
2005
- 2005-09-16 KR KR1020050086821A patent/KR100659138B1/en active IP Right Grant
-
2006
- 2006-09-08 JP JP2008531009A patent/JP5524483B2/en active Active
- 2006-09-08 WO PCT/KR2006/003579 patent/WO2007032624A1/en active Application Filing
- 2006-09-08 US US12/064,997 patent/US20090176810A1/en not_active Abandoned
-
2011
- 2011-06-22 US US13/067,719 patent/US8563564B2/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5665367A (en) * | 1996-09-27 | 1997-09-09 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Skin care compositions containing naringenin and/or quercetin and a retinoid |
US20030211184A1 (en) * | 1999-02-02 | 2003-11-13 | Archer-Daniels-Midland Company | Process for extracting polyphenolic antioxidants from purine-containing plants |
US6861062B2 (en) * | 2000-03-01 | 2005-03-01 | Victor Silva | Skin cream |
US20020106388A1 (en) * | 2000-11-24 | 2002-08-08 | Pugliese Peter T. | Formulation of flavones and isoflavones for treatment of cellulite |
US20050031737A1 (en) * | 2002-11-22 | 2005-02-10 | Lines Thomas Christian | Antioxidative compositions |
US20040161435A1 (en) * | 2003-02-14 | 2004-08-19 | Gupta Shyam K. | Skin Firming Anti-Aging Cosmetic Mask Compositions |
US20050003024A1 (en) * | 2003-03-04 | 2005-01-06 | The Procter & Gamble Company | Regulation of mammalian hair growth |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011038210A3 (en) * | 2009-09-25 | 2011-10-20 | Opkocurna, Inc. | Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity |
US11390868B2 (en) | 2009-09-25 | 2022-07-19 | Curna, Inc. | Treatment of filaggrin (FLG) related diseases by modulation of FLG expression and activity |
US10336797B2 (en) | 2009-11-23 | 2019-07-02 | Research Development Foundation | Recombinant filaggrin polypeptides for cell importation |
US11098097B2 (en) | 2009-11-23 | 2021-08-24 | Research Development Foundation | Recombinant filaggrin polypeptides for cell importation |
US9132294B2 (en) | 2010-06-30 | 2015-09-15 | Avon Products, Inc. | Compositions and methods for stimulation MAGP-1 to improve the appearance of skin |
US9409860B2 (en) | 2010-06-30 | 2016-08-09 | Avon Products Inc. | Cosmetic use of N-substituted sulfonyloxybenzylamines and related compounds |
US9999587B2 (en) | 2010-06-30 | 2018-06-19 | Avon Products, Inc. | Compositions and methods for stimulation MAGP-1 to improve the appearance of skin |
US10849840B2 (en) | 2010-06-30 | 2020-12-01 | New Avon Llc | Compositions and methods for stimulation MAGP-1 to improve the appearance of skin |
WO2022122167A1 (en) | 2020-12-11 | 2022-06-16 | Symrise Ag | Medicament for preventing or treating pathologic conditions of human skin (i) |
Also Published As
Publication number | Publication date |
---|---|
JP5524483B2 (en) | 2014-06-18 |
US20120010226A1 (en) | 2012-01-12 |
US8563564B2 (en) | 2013-10-22 |
JP2009508850A (en) | 2009-03-05 |
KR100659138B1 (en) | 2006-12-19 |
WO2007032624A1 (en) | 2007-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8563564B2 (en) | Composition for skin external application containing gallocatechin gallate for moisturizing effect on the skin | |
US10092493B2 (en) | Composition of skin external application for anti-aging | |
DE102004028302B4 (en) | Stimulating the synthesis and activity of an isoform of lysyl oxidase-like LOXL to stimulate the formation of elastic fibers | |
EP2043630B1 (en) | 6, 9-disubstituted purine derivatives for cosmetic use | |
US20100166814A1 (en) | Cosmetic Composition Containing At Least Two Osmolytes With A Moisturizing Or Antiaging Effect | |
WO1997035618A1 (en) | Dermatologic preparation | |
JP2002540126A (en) | Cosmetic or dermatological composition containing at least one substance for increasing the function and / or expression of skin cell CD44 membrane receptor | |
US10307361B2 (en) | Vesicles containing saccharide isomerate, hydrolyzed lupine protein, and intercorneocyte lipid mimetics as active ingredient, and composition for skin external application comprising the same | |
CN106232097B (en) | Cosmetic composition for moisturizing skin | |
JP2009298752A (en) | Skin care preparation composition for external use | |
KR20090056300A (en) | Cosmetic composition for improving the skin elasticity | |
US11771637B2 (en) | Skin care composition and method of using the same | |
JP5705397B2 (en) | Use of substances to protect FGF-2 or FGF-β growth factors | |
EP2510112B1 (en) | Method for screening active agents that stimulate the expression of cert to improve the skin's barrier function | |
Levin et al. | Animal, human, and in vitro test methods for predicting skin irritation | |
CN112438898A (en) | Cosmetic composition for moisturizing skin and improving skin barrier comprising electrolyte material | |
KR20190051880A (en) | Cosmetic composition for improving skin wrinkles and elasticity | |
KR20130057394A (en) | Skin external composition comprising theanine derivative | |
US20140220069A1 (en) | Active ingredient derived from torulaspora delbrueckii and cosmetic use for improving and/or repairing the barrier function of the skin | |
US20080124289A1 (en) | Use of an alkyloxazolidinone as a moisturizing cosmetic agent and method of moisturizing the skin | |
KR20030002477A (en) | Cosmetic composition for skin moisturizer | |
KR20010010727A (en) | Composition for external application to the skin | |
KR101373715B1 (en) | Cosmetic composition promoting cornified envelope formation | |
KR20130120741A (en) | Cosmetic composition promoting cornified envelope formation | |
US20120237941A1 (en) | Method for screening active agents that stimulate the expression of arnt2 to improve the skin's barrier function |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AMOREPACIFIC CORPORATION, KOREA, REPUBLIC OF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHIN, HYUN JUNG;KIM, JEONG KI;KIM, SU NAM;AND OTHERS;REEL/FRAME:021395/0068 Effective date: 20080722 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |